Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 + Dalpicicilip in Recurrent/Metastatic CDKN2A-Variant HNSCC
NCT06509997Phase 2Not yet recruiting
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of becotatug vedotin, dalpiciclib in head and neck squamous cell carcinoma (HNSCC). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
becotatug vedotindalpiciclib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06509997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06509997.